Access and Utilization of New Antidepressant and Antipsychotic Medications. Reference List


1. Health Care Financing Administration(now known as Centers for Medicare and Medicaid Services(CMS)). National health expenditures projections. 1999.
2. National health expenditures aggregate amounts and average annual percent change, by type of expenditure: selected calendar years 1960-97. Accessed November 17, 1999. Web Page. Available at:
3. The National Institute for Health Care Management. Issue brief: factors affecting the growth of prescription drug expenditures. 1999.
4. The Lewin Group. Health plan benefit barriers to access to pharmaceutical therapies for behavioral health. The Substance Abuse and Mental Health Services Administration; 1998.
5. Physicians' Desk Reference. 53 ed. Montvale, NJ: Medical Economics Company; 1999.
6. Croghan TW, Johnstone BM, Buesching DP, Kessler RC. Information needs for medication coverage decisions in a state Medicaid program. Med Care. 1999;37:AS24-31.
7. Calkins D, Fernadopulle RJ, Marino BS e. Health Care Policy. Cambridge, MA: Blackwell Science; 1995.
8. Levy RA, Cocks D. Component Management Fails to Save Health Care System Costs. Resong, VA: National Pharmaceutical Council; 1996.
9. Moore WJ, Newman RJ. US Medicaid drug formularies: do they work? Pharmacoeconomics. 1992;1:28-31.
10. Horn SD. HMO formularies and care costs. Lancet. 1996;348:619-20.
11. Horn SD. Unintended consequences of drug formularies. Am J Health Syst Pharm. 1996;53:2204-6.
12. Ross-Degnan D, Soumerai SB. HMO formularies and care costs. Lancet. 1996;347:1264.
13. Streja DA, Hui RL, Streja E, McCombs JS. Selective contracting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants. Am J Managed Care. 1999;5:1133-42.
14. Scott-Levin. Press Release: The Pharmaceutical Industry: More Reps and More Promotion Fuel New Launches. June 18, 1999.
15. Scott-Levin. Press Release: Antidepressants Top Medical Journal Advertising. August 26, 1999.
16. Issue Brief: Factors Affecting the Growth of Prescription Drugs Expenditures. National Institute for Health Care Management; 1999.
17. Scott-Levin. Press Release: Spending on Rx Drug Ads Reaches $1.1 Billion in First 10 Months of 1998; Surpasses 1997 Total. January 27, 1999.
18. Government of the United States. Washington, DC: General Accounting Office; 1996.
19. The Lewin Group. Pharmaceutical Benefits Under State Medical Assistance. Reston, VA: National Pharmaceutical Council; 1998.
20. Smith SJ. HMO Raises Drug Co-Pay. Rochester Democrat and Chronicle. August 9, 1999:(A);8A.
21. Drug formularies. Is their growth among HMOs leveling off? Med Econ. 1997;74:39.
22. Managed care outlook. Formularies get stricter. Manag Care. 1997;6:130.
23. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry. 1999;60 Suppl 3:3-7; discussion 8.
24. Lawrence J. Formularies tighten and physicians adapt. Manag Care. 1998;7:23-6, 29-30.
25. Richardson S. Letter to State Medicaid Directors. February 12, 1998.
26. Walser BL, Ross-Degnan D, Soumerai SB. Do open formularies increase access to clinically useful drugs? Health Aff. 1996;15:95-109.
27. The Lewin Group. Pharmaceutical Benefits Under State Medical Assistance. Reston, VA: National Pharmaceutical Council; 1996.
28. Data watch. Is this the way to manage pharmacy costs? Bus Health. 1997;15:94.
29. Cassak D. Managing Physicians, Managing Prescriptions. In Vivo. 1998;April:37-47.
30. Depression Guideline Panel. Depression in Primary Care: Volume 2. Treatment of Major Depression. Clinical Practice Guideline, Number 5. Rockville, MD: U.S. Department of Health and Human Services, Public Health SErvice, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551. 1993.
31. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1-10.
32. American Psychiatric Association. Practice Guidelines for Major Depressive Disorder in Adults. Washington, DC: American Psychiatric Association. 1993.
33. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. Washington, DC: American Psychiatric Association; 1997.
34. Shon SP, Crismon ML, Toprac MG, et al. Mental health care from the public perspective: the Texas Medication Algorithm Project. J Clin Psychiatry. 1999;60 Suppl 3:16-20; discussion 21.
35. TMAP website. accessed December 8, 1999. Web Page. Available at:
36. Department of Veterans Affairs VHA. Publication No. 97-0006. 1997.
37. PCS website. Clinical formulary and prescribing guidelines. Accessed January 5, 2000. Web Page. Available at:
38. Magellan Develops Guidelines for Antidepressant Use. PharmacoEconomics & Outcomes News. 1999;214:7.
39. Sullivan S, Mather D, Augenstein D, Atherly D, Fullerton DSP. Guidelines for the submission of clinical and economic data supporting formulary consideration. Am J Managed Care. 1999;5:277.
40. Langley PC, Martin RE. Managed care guidelines for the economic evaluation of pharmaceuticals. Am J Manag Care. 1997;3:1013-21.
41. Tran PB, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-18.
42. Revicki D, Simon G, VonKorff M, Wagner E, Heiligenstein J, Luce B. Cost-effectiveness of fluoxetine versus tricyclic antidepressants: a randomized study in primary care. Annu Meet Int Soc Technol Assess Health Care. 1996;12:32.
43. Celexa scripts for patients under 20 account for 4% of use--Forest. The Pink Sheet. 1999;61:14-15.
44. Conner TM, Crismon ML, Still DJ. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother. 1999;33:364-72.
45. Sclar DA, Skaer TL, Robison LM, Stowers JK. Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions. Depress Anxiety. 1998;8 Suppl 1:121-7.
46. Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics. 1998;13:61-70.
47. Stewart A. Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord. 1998;48:125-33.
48. Hylan TR, Buesching DP, Tollefson GD. Health economic evaluations of antidepressants: a review. Depress Anxiety. 1998;7:53-64.
49. Davis R, Wilde M. Sertraline: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics. 1996;10:409-31.
50. Zito J. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Schizophrenia. 1998;21:181-202.
51. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs. Ann Pharmacother. 1999;33:210-7.
52. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for teh treatment of schizophrenia. Schizophrenia Research.1999;35:S101-109.
53. Foster RH, Goa KL. Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics. 1999;15:611-40.
54. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics. 1998;14:97-133.
55. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry. 1997;58 Suppl 10:50-4.
56. Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. J Clin Psychiatry.1999;60 Suppl 1:7-11; discussion 28-30.
57. Wilde MI, Benfield P. Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics. 1998;13:543-61.
58. Wilde MI, Whittington R. Paroxetine. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics. 1995;8:62-81.
59. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci. 1997;22:256-66.
60. Mulrow D.C., William J.W., Trivedi M., et. al. Rockville, MD. Agency for Health Care Policy and Research. 1999. AHCPR Publication ; No. 99-E014.
61. Rice DP, Miller LS. The economic burden of affective disorders. Br J Psychiatry Suppl. 1995:34-42.
62. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-18.
63. Smith W, Sherrill A. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO. Medical Interface. 1996;88-92.
64. Boyer W, Feighner J. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. Jonsson B RJ, editors. Health Economics of Depression. Chichester, West Sussex: Wiley; 65-75.
65. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care.Psychiatr Serv. 1997;48:1420-6.
66. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization.Clin Ther. 1994;16:715-30; discussion 74.
67. Sclar DA, Skaer TL, Robison LM, Galin RS, Legg RF, Nemec NL. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. J Clin Psychiatry. 1998;59 Suppl 2:13-7.
68. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord. 1998;47:71-9.
69. Obenchain RL, Melfi CA, Croghan TW, Buesching DP. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy.Pharmacoeconomics. 1997;11:464-72.
70. Bentkover J, Feighner J. Cost analysis of paroxetine versus imipramine in major depression. Pharmacoeconomics. 1995;8:223-232.
71. Jonsson B, Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994;164:665-73.
72. Lapierre Y, Bentkover J, Schainbaum S, Manners S. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Can J Psychiatry. 1995;40:370-7.
73. Skaer T, Sclar D, Robison L, Galin R, Legg R, Nemic N. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Current Therapeutic Research. 1995;56:556-67.
74. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care.Journal of Affective Disorders. 1996;38:97-111.
75. Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther. 1995;17:136-53.
76. Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.Pharmacoeconomics. 1997;12:286-96.
77. Griffiths RI, Sullivan EM, Frank RG, et al. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression. Pharmacoeconomics. 1999;15:495-505.
78. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997;58:47-58.
79. Boyer P, Danion J, Bisserbe J, Hotton J, Troy S. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. Pharmacoeconomics. 1998;13:157-69.
80. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res. 1995;23:395-412.
81. Rupp A, Keith J. The cost of schizophrenia: assessing the burden. Psychiatr Clin North Am. 1993;16:413-23.
82. Albright P, Livingstone S, Keegan D, Ingham M, Shrikhande S, Le Lorier J. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. A retrospective analysis using the Saskatchewan health linkable database. Clin Drug Invest. 1996;11:289-99.
83. Wyatt R, Henter I, Leary M, et al. An economic evaluation of schizophrenia. Soc Pyschiatry Psychiatr Epidemiol. 1995;31:196-205.
84. Carter C, Stevens M, Durkin M. Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah.Clin Ther. 1998;20:352-63.
85. Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull. 1998;34:75-81.
86. Lacro JP, Vonderscher CN, Kodsi AB ea. Cost analysis of risperidone in veterans with schizophrenia or schizoaffective disorder. Annual Meeting of the New Clinical Drug Evaluation Unit: Boca Raton (FL), USA.
87. Philipp M. Risperidone in patients with schizophrenia: acute responses and effects on one-year hospitalization rates. 149th Annual Meeting of the American Psychiatric Association: New York.
88. Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, Lawrence BJ. Impact of risperidone on the use of mental health care resources. Psychiatr Serv. 1997;48:1153-9.
89. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther. 1993;15:917-26.
90. Lindstrom E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther. 1995;17:402-12.
91. Frankenberg FR, Zanarini MC, Cole JO, McElroy SL. Hospitalization rates among clozapine-treated patients. A prospective cost-benefit analysis. Ann Clin Psychiatry. 1992;4:247-50.
92. Wilson WH. Clinical review of clozapine treatment in a state hospital. Hospital and Community Psychiatry. 1992;43:700-3.
93. Guest JF, Hart WM, Cookson RF, Lindstrom E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. British Journal of Medical Economics. 1996;10:69-67.
94. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care. 1998;4:345-55.
95. Tollefson GD, Beaseley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65.
96. Galvin PM, Knezek LD, Rush AJ, Toprac MG, Johnson B. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin Ther. 1999;21:1105-16.
97. Nightengale BS, Garrett L, Waugh S, Lawrence BJ, Andrus J. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. Am J Manag Care. 1998;4:360-6.
98. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry. 1996;57:337-45.
99. Mahmoud R, Engelhart L, Ollendorf D, Oster G. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry. 1999;60 Suppl 3:42-7; discussion 48.
100. Mahmoud R et al. 36th Annual Meeting of the American College of Neuropsychopharmacology: Kameula, Hawaii.
101. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther. 1998;20:196-213.
102. LeLorier J, Petersen T, Albright PS. A retrospective cohort study of the RAMQ database to study the impact of risperidone use in the province of Quebec. 150th Annual Meeting of the American Psychiatric Association: San Diego.
103. Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacol Bull. 1998;34:373-82.
104. Hart WM, Lindstrom E, Guest JF. Economic impact of theuse of risperidone for the treatment of chronic schizophrenia in Ireland. Ir J Psychiatry. 1997;16:12-6.
105. Thompson D. Cost of switching from neuroleptics to risperidone and clozapine: a pilot study of the San Diego County Mental Health Services. Clin Drug Invest. 1997;14:428-33.
106. Schiller MJ, Shumway M, Hargreaves WA. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr Serv. 1999;50:228-32.
107. Obenchain RL JB. Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Information Journal. 1999;33:191-209.
108. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Pharmacoeconomics. 1999;15:469-80.
109. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol.Pharmacoeconomics. 1998;13:575-88.
110. Sacristan JA, Gomez C, Salvador-Carulla L. Analisis coste-effectividad de olanzapine frenta a haloperidol en el tratamiento de la esquizofrenia en Espana. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1997;25:225-34.
111. Post HA, van Hout BA. Cost effectiveness of olanzapine in comparison to risperidone and haloperidol. Annu Meet Int Soc Technol Assess Health Care. 1997;13:134.
112. Spannheimer A, Clouth J. Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: a comparison of olanzapine and haloperidol. Data on File, Eli Lilly and Company. 1999.
113. Sacristan JA, Gomez JC, Martin J. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. Clin Drug Invest. 1998;15:29-35.
114. Weiss MA, McCollum M. Cost impact of using olanzapine at a Veterans Affairs Medical Center (abstract). ValueHealth. 1998;1:25.
115. Hong WW, Rak IW, Ciuryla VT, et al. Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication. Schizophr Res. 1998;32:51-8.
116. Grainger DL, Edgell ET, Anderson SW, et al. Resource use and quality of life of olanzapine cmopared with risperidone: results from an international randomized clinical trial. 11th Annual Congress of the European College of Neuropsychopharmacology: Paris, France.
117. Risperdal vs. Zyprexa battle rages on. The Pink Sheet. 1998;2385:21.
118. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med.1997;337:809-15.
119. Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L. Clozapine eligibility among state hospital patients.Schizophr Bull. 1996;22:15-25.
120. Revicki et al. Hosp Community Psychiatry. 1990;41:850-54.
121. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry.1990;41:882-5.
122. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry.1993;150:1630-8.
123. Ghaemi SN, Ziegler DM, Peachey TJ, Goodwin FK. Cost-effectiveness of clozapine therapy for severe psychosis. Psychiatr Serv.1998;49:829-31.
124. Luchins DJ, Hanrahan P, Shinderman M, Lagios L, Fichtner CG. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. Psychiatr Serv. 1998;49:1034-8.
125. Reid WH. The treatment of psychosis: resetting the drug cost 'thermostat'. J Clin Psychiatry. 1994;55 Suppl B:166-8.